Siolta Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
Allergic Disease Onset Prevention Study
Phase 1
Active, not recruiting
- Conditions
- Atopic DermatitisType 1 Hypersensitivity
- Interventions
- Biological: STMC-103HBiological: Placebo
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Siolta Therapeutics, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT05003804
- Locations
- 🇺🇸
UT Southwestern/Children's Health, Dallas, Texas, United States
🇺🇸Dell Medical School at UT Austin, Austin, Texas, United States
🇦🇺The Children's Hospital at Westmead, Westmead, New South Wales, Australia
A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy
Phase 1
- Conditions
- Atopic Immunoglobulin E-Mediated Allergic Disorder
- Interventions
- Biological: STMC-103HBiological: Placebo
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Siolta Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03819881
- Locations
- 🇺🇸
Bensch Clinical Research LLC, Stockton, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
© Copyright 2025. All Rights Reserved by MedPath